Tag Archives: side effect

Rise in Teen Marijuana Use Stalls, Use of Synthetic Marijuana and ‘Bath Salts’ is Very Low

ANN ARBOR — National samples of 45,000 to 50,000 students in three grades (8, 10, and 12) have been surveyed every year since 1991 as part of the nationwide Monitoring the Future study. Among the most important findings from this year’s survey of U.S. secondary school students are the following:

Marijuana. After four straight years of increasing use among teens, annual marijuana use showed no further increase in any of the three grades surveyed in 2012. The 2012 annual prevalence rates (i.e., percent using in the prior 12 months) were 11%, 28%, and 36% for 8th, 10th, and 12th graders, respectively. (Among the 8th graders there was a modest decline across the past two years—from 13.7% in 2010 to 11.4% in 2012—that reached statistical significance.) (more…)

Read More

Promising Nanotechnology

Nanotechnology for drug delivery shows promise in treatment of pediatric leukemia

Nanotechnology developed by Delaware scientists could potentially deliver chemotherapy to children in a way that attacks cancer cells without harming healthy cells, greatly reducing side effects.

The work, conducted by researchers in the University of Delaware’s Department of Materials Science and Engineering and Nemours Center for Childhood Cancer Research, was published this month in the journal Molecular Pharmaceutics. (more…)

Read More

Medication Beliefs Strongly Affect Individuals’ Management of Chronic Diseases, MU Expert Says

Health practitioners should use behavior-change tactics so patients take medications as prescribed

COLUMBIA, Mo. – Nearly half of patients taking medications for chronic conditions do not strictly follow their prescribed medication regimens. Failure to use medications as directed increases patients’ risk for side effects, hospitalizations, reduced quality of life and shortened lifespans. Now, a University of Missouri gerontological nursing expert says patients’ poor adherence to prescribed medication regimens is connected to their beliefs about the necessity of prescriptions and concerns about long-term effects and dependency.

MU Assistant Professor Todd Ruppar found that patients’ beliefs about the causes of high blood pressure and the effectiveness of treatment alternatives significantly affected their likelihood of faithfully following prescribed medication regimens. In his pilot study, Ruppar focused on older patients’ adherence to medication treatments that control high blood pressure, a condition that affects nearly 70 million adults in the U.S. and can lead to heart disease and stroke. (more…)

Read More

Gold Nanoparticle Prostate Cancer Treatment Found Safe in Dogs, MU Study Shows

New treatment may have fewer side effects than traditional cancer therapy

COLUMBIA, Mo. ­— Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form of prostate cancer treatment that uses radioactive gold nanoparticles, and was developed at MU, is safe to use in dogs. Sandra Axiak-Bechtel, an assistant professor in oncology at the MU College of Veterinary Medicine, says that this is a big step for gold nanoparticle research.

“Proving that gold nanoparticles are safe to use in the treatment of prostate cancer in dogs is a big step toward gaining approval for clinical trials in men,” Axiak-Bechtel said. “Dogs develop prostate cancer naturally in a very similar way as humans, so the gold nanoparticle treatment has a great chance to translate well to human patients.” (more…)

Read More

Researchers Uncover How New Melanoma Drug Accelerates Secondary Skin Cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.

Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and Plexxikon, have elucidated the mechanism by which the drug excels at fighting melanoma but also allows for the development of skin squamous-cell carcinomas. (more…)

Read More